Looks like Resverlogix posted the June fact sheet on their website. It reiterates that BETonMACE is fully enrolled with top-line data expected around the end of 2018.

As for recent events, it lists:

1) The recent ERA-EDTA conference in Copenhagen where they presented two posters (link to the two posters here and here).

2) The upcoming BIO-International 2018 conference in Boston, at which they are presenting during the afternoon of Wednesday June 6th.

3) The upcoming American Diabetes Association 2018 conference in Orlando June 22-26, 2018. In the ADA 2018 conference app, I was able to find that Norman Wong is presenting a poster on Sunday June 24th. Abstract embargoed right now, but very likely similar if not identical to abstract #669 at Vascular Discovery and IAS 2018 abstract referenced below with the same title.

1136-P - Apabetalone (RVX-208) Lowers Major Adverse Cardiac Events (MACE) in Diabetes Mellitus Patients with CVD by Attentuating Monocyte Adhesion to Endothelial Cells. 

However, there are some "alternative facts" not listed on their current fact sheet.

1) Vascular Discovery 2018 conference that they attended and prestented at earlier in May. Full abstracts for #257 and #669 can be found here.

2) International Symposium on Atherosclerosis conference in Toronto June 9-12, 2018 at which they are presenting an abstract very similar to #669 presented at Vascular Discovery 2018.

3) Gordon Research Conference "Lipoprotein Metabolism in the Brain and Circulation and Its Role in Disease" in Waterville Valley, NH June 10-15, 2018. Norman Wong has a half hour time slot oral presentation entitled "Benefits of Selective Inhibition of Epigenetic BET Proteins in Cardiovascular Disease" in the session "Novel Therapies and Diagnostic Approaches for Vascular Lipoprotein Disorders."

This Gordon Research Conference is a sweet conference to be presenting at. Alan Remaley and Cheryl Wellington are chairing the conference and they are both huge apoAI/HDL researchers. These are top notch basic and clinical researchers in attendance. There is only one oral presentation at a time, unlike the huge conferences that feature multiple simultaneous presentations. A much more intimate conference. More in depth interaction with folks since you're with the same modestly sized group for a few days. A great opportunity to highlight apabetalone and get the word out. Looks like Norman is also participating in a panel discussion on Careers in Academia and Industry at a Gordon Research Seminar June 10 that precedes the larger Gordon Research Conference. Thanks to rndtbl over on Investor Village for first bringing this to my attention.

It'll be a busy June for the Resverlogix crew! Hopefully some good news will come out soon on the SSRA/DSMB report for BETonMACE that Resverlogix can brag about at these many events! 

BearDownAZ